.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,333,990

« Back to Dashboard

Details for Patent: 8,333,990

Title:Solid pharmaceutical dosage form
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Inventor(s): Rosenberg; Joerg (Ellerstadt, DE), Reinhold; Ulrich (Heidelberg, DE), Liepold; Bernd (Dossenheim, DE), Berndl; Gunther (Herxheim, DE), Breitenbach; Joerg (Mannheim, DE), Alani; Laman (Foster City, CA), Ghosh; Soumojeet (Lansdale, PA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Sep 13, 2010
Application Number:12/880,766
Claims:1. A method of preparing a solid dosage form, comprising solidifying a melt which comprises: ritonavir and lopinavir, a pharmaceutically acceptable surfactant having an HLB value of from 4 to 10, and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C.

2. The method of claim 1, wherein said solidified melt comprises a solid dispersion which comprises: ritonavir and lopinavir, the surfactant, and the water-soluble polymer.

3. The method of claim 1, wherein said solidified melt comprises a glassy or solid solution which comprises: ritonavir and lopinavir, the surfactant, and the water-soluble polymer.

4. The method of claim 1, wherein said water-soluble polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate, and said surfactant is a sorbitan mono fatty acid ester.

5. The method of claim 1, wherein said water-soluble polymer is copovidone, and said surfactant is sorbitan monolaurate.

6. The method of claim 5, wherein said water-soluble polymer is present in an amount of from 50% to 85% by weight of the solidified melt, and said surfactant is present in an amount of from 2% to 20% by weight of the solidified melt.

7. The method of claim 1, wherein said water-soluble polymer is selected from the group consisting of homopolymer of N-vinyl lactam, copolymer of N-vinyl lactam, cellulose ester, cellulose ether, polyalkylene oxide, polyacrylate, polymethacrylate, polyacrylamide, polyvinyl alcohol, vinyl acetate polymer, oligosaccharide, and polysaccharide, and wherein said surfactant is selected from the group consisting of polyoxyethylene alkyl ether, polyoxyethylene alkylaryl ether, polyethylene glycol fatty acid ester, alkylene glycol fatty acid mono ester, sucrose fatty acid ester, and sorbitan fatty acid mono ester.

8. The method of claim 1, wherein said water-soluble polymer is selected from the group consisting of homopolymer of N-vinyl pyrrolidone, copolymer of N-vinyl pyrrolidone, copolymer of N-vinyl pyrrolidone and vinyl acetate, copolymer of N-vinyl pyrrolidone and vinyl propionate, polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxyalkylcelluloses, hydroxypropylcellulose, hydroxyalkylalkylcellulose, hydroxypropylmethylcellulose, cellulose phthalate, cellulose succinate, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose acetate succinate, polyethylene oxide, polypropylene oxide, copolymer of ethylene oxide and propylene oxide, methacrylic acid/ethyl acrylate copolymer, methacrylic acid/methyl methacrylate copolymer, butyl methacrylate/2-dimethylaminoethyl methacrylate copolymer, poly(hydroxyalkyl acrylate), poly(hydroxyalkyl methacrylate), copolymer of vinyl acetate and crotonic acid, partially hydrolyzed polyvinyl acetate, carrageenan, galactomannan, and xanthan gum, and wherein said surfactant is selected from the group consisting of polyoxyethylene (3) lauryl ether, polyoxyethylene (5) cetyl ether, polyoxyethylene (2) stearyl ether, polyoxyethylene (5) stearyl ether, polyoxyethylene (2) nonylphenyl ether, polyoxyethylene (3) nonylphenyl ether, polyoxyethylene (4) nonylphenyl ether, polyoxyethylene (3) octylphenyl ether, PEG-200 monolaurate, PEG-200 dilaurate, PEG-300 dilaurate, PEG-400 dilaurate, PEG-300 distearate, PEG-300 dioleate, propylene glycol monolaurate, sucrose monostearate, sucrose distearate, sucrose monolaurate, sucrose dilaurate, sorbitan mono laurate, sorbitan monooleate, sorbitan monopalnitate, and sorbitan stearate.

9. The method of claim 1, wherein the melt has a temperature in a range of from 100.degree. C. or 140.degree. C.

10. The method of claim 9, wherein the melt is prepared in an extruder.

11. The method of claim 9, wherein the melt is prepared in a twin screw extruder.

12. The method of claim 5, wherein the melt has a temperature in a range of from 100.degree. C. or 140.degree. C. and is prepared in a twin screw extruder.

13. The method of claim 1, further comprising: milling the solidified melt to granules, compacting the granules, together with at least one additive, into a tablet, and coating said tablet with a film coat to produce said dosage form, wherein said additive is a flower regulator, a disintegrant, a bulking agent, or a lubricant.

14. The method of claim 5, further comprising: milling the solidified melt to granules, compacting the granules, together with at least one additive, into a tablet, and coating said tablet with a film coat to produce said dosage form, wherein said additive is a flower regulator, a disintegrant, a bulking agent, or a lubricant.

15. The method of claim 14, wherein said ritonavir and lopinavir are present in an amount of from 5% or 30% by weight of said dosage form, said water-soluble polymer is present in an amount of from 50% to 85% by weight of said dosage form, and said surfactant is present in an amount of from 2% to 20% by weight of said dosage form.

16. A method of preparing a solid dosage form, comprising: solidifying a melt, milling the solidified melt to granules, compacting the granules, together with at least one additive, into a tablet, and coating said tablet with a film coat to produce said solid dosage form, wherein said melt comprises (1) ritonavir and lopinavir, (2) a pharmaceutically acceptable surfactant which has an HLB value of from 4 to 10, or a combination of pharmaceutically acceptable surfactants which has an HLB value of from 4 to 10, and (3) a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., or a combination of pharmaceutically acceptable water-soluble polymers having a Tg of at least 50.degree. C., and wherein said additive is a flower regulator, a disintegrant, a bulking agent, or a lubricant.

17. The method of claim 16, wherein said solidified melt comprises 4.17% by weight ritonavir, 16.67% by weight lopinavir, 71.16% by weight copovidone, 7.0% by weight sorbitan monolaurate, and 1.0% by weight colloidal silica.

18. A method of preparing a solid dosage form, comprising: solidifying a first melt and a second melt, milling the solidified first and second melts to granules, compacting the granules, together with at least one additive, into a tablet, and coating said tablet with a film coat to produce said solid dosage form, wherein said firs melt comprises (1) ritonavir, (2) a pharmaceutically acceptable surfactant which has an HLB value of from 4 to 10, or a combination of pharmaceutically acceptable surfactants which has an HLB value of from 4 to 10, and (3) a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., or a combination of pharmaceutically acceptable water-soluble polymers having a Tg of at least 50.degree. C., wherein said second melt comprises (1) lopinavir, (2) a pharmaceutically acceptable surfactant which has an HLB value of from 4 to 10, or a combination of pharmaceutically acceptable surfactants which has an HLB value of from 4 to 10, and (3) a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., or a combination of pharmaceutically acceptable water-soluble polymers having a Tg of at least 50.degree. C., and wherein said additive is a flower regulator, a disintegrant, a bulking agent, or a lubricant.

19. A method of preparing a solid dosage form, comprising solidifying a first melt and a second melt, wherein said first melt comprises (1) ritonavir, (2) a pharmaceutically acceptable surfactant having an HLB value of from 4 to 10, or a combination of pharmaceutically acceptable surfactants having an HLB value of from 4 to 10, and (3) a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., or a combination of pharmaceutically acceptable water-soluble polymers having a Tg of at least 50.degree. C., and wherein said second melt comprises (1) lopinavir, (2) a pharmaceutically acceptable surfactant having an HLB value of from 4 to 10, or a combination of pharmaceutically acceptable surfactants having an HLB value of from 4 to 10, and (3) a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., or a combination of pharmaceutically acceptable water-soluble polymers having a Tg of at least 50.degree. C.

20. A method of preparing a solid dosage form, comprising formulating ritonavir and lopinavir in solid solution, wherein said solid solution comprises a pharmaceutically acceptable surfactant having an HLB value of from 4 to 10 or a combination of pharmaceutically acceptable surfactants having an HLB value of from 4 to 10, and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. or a combination of pharmaceutically acceptable water-soluble polymers having a Tg of at least 50.degree. C.

21. The method of claim 20, further comprising shaping said solid dosage form into a tablet.

22. The method of claim 20, further comprising subdividing said solid solution to granules.

23. The method of claim 22, further comprising compacting said granules into a tablet.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc